Tango Therapeutics price target raised to $33 from $19 at Wedbush

Wedbush raised the firm’s price target on Tango Therapeutics (TNGX) to $33 from $19 to incorporate recent financing activities and evolving vopimetostat development, while keeping an Outperform rating on the shares following quarterly results and business update. The firm looks forward to the continued development of PRMT5i assets, as well as data updates coming later this year.